Jan Skvarka - 09 Sep 2022 Form 4 Insider Report for Zentalis Pharmaceuticals, Inc. (ZNTL)

Role
Director
Signature
/s/ Andrea Paul, attorney-in-fact for Jan Skvarka
Issuer symbol
ZNTL
Transactions as of
09 Sep 2022
Net transactions value
$0
Form type
4
Filing time
12 Sep 2022, 07:07:52 UTC
Previous filing
19 Nov 2021
Next filing
24 Mar 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ZNTL Common Stock Award $0 +36,606 $0.000000 36,606 09 Sep 2022 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The restricted stock units ("RSUs") were granted by the Issuer pursuant to the Issuer's Non-Employee Director Compensation Program. One third of the RSUs will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date.